DCM
VIR icon

Dupont Capital Management’s Vir Biotechnology VIR Stock Holding History

Dupont Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,699
Closed -$93.6K – 1206
2022
Q4 		$93.6K Buy
+3,699
New +$90.7K ﹤0.01% 960
2022
Q3 		– Sell
-5,175
Closed -$132K – 1684
2022
Q2 		$132K Hold
5,175
– – 0.01% 1123
2022
Q1 		$133K Buy
5,175
+1,014
+24% +$30.1K 0.01% 1208
2021
Q4 		$174K Buy
+4,161
New +$163K 0.01% 1166
2021
Q2 		– Sell
-8,746
Closed -$448K – 1851
2021
Q1 		$448K Sell
8,746
-2,570
-23% -$139K 0.01% 994
2020
Q4 		$303K Buy
11,316
+6,179
+120% +$201K 0.01% 1032
2020
Q3 		$176K Buy
+5,137
New +$221K ﹤0.01% 1137

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Dupont Capital Management's VIR Position: Q1 2023 in Review

Dupont Capital Management sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 3,699 shares — an estimated $93.6K sold.

Dupont Capital Management first reported a position in VIR in Q3 2020 and held it in 7 quarters. The position peaked at $448K in Q1 2021. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Dupont Capital Management reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 3,699 Vir Biotechnology shares in Q1 2023, an estimated $93.6K.
  • Dupont Capital Management first reported a position in Vir Biotechnology in Q3 2020 and held it in 7 quarters.
  • Dupont Capital Management's Vir Biotechnology position peaked at $448K in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.